Medicare Enrolled
Dr. Madhuri Yalamanchili, MD
Hematology & Oncology · Binghamton, NY
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Yalamanchili from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Yalamanchili?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Yalamanchili
Dr. Madhuri Yalamanchili is a hematology & oncology specialist in Binghamton, NY, with 20 years of NPI registration. Based on federal Medicare data, Dr. Yalamanchili performed 25,877 Medicare services across 2,234 unique beneficiaries.
Between the years covered by Open Payments, Dr. Yalamanchili received a total of $17,941 from 89 pharmaceutical and/or device companies across 838 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Yalamanchili is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice
▲ Top 18% volume in NY
$17,941 industry payments
Medicare Practice Summary
Medicare Utilization ↗25,877
Medicare services
Top 18% in NY for hematology & oncology
2,234
Unique beneficiaries
$11
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~1,294 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Oxaliplatin chemotherapy injection This procedure involves the administration of oxaliplatin, a chemotherapy medication, via injection. The dosage specified is 0.5 mg. |
8,898 | $0 | $3 |
| Anti-nausea injection (aprepitant) | 3,640 | $1 | $5 |
| Denosumab injection (Prolia/Xgeva) | 3,180 | $19 | $69 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
2,724 | $0 | $1 |
| Anti-nausea injection (Aloxi/palonosetron) | 1,020 | $1 | $5 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
879 | $8 | $75 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
798 | $8 | $100 |
| Comprehensive metabolic blood panel A blood test that measures a group of chemicals, including glucose, electrolytes, and kidney and liver function markers. |
672 | $10 | $100 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
569 | $92 | $334 |
| Anti-nausea injection (ondansetron/Zofran) | 552 | $0 | $2 |
| Pegfilgrastim injection, 0.5 mg An injection of pegfilgrastim, a medication that stimulates the production of white blood cells. This specific code applies to the brand-name drug and excludes biosimilar versions. |
492 | $74 | $510 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
370 | $12 | $100 |
| Pegfilgrastim-apgf injection An injection of pegfilgrastim-apgf, a biosimilar medication. The dose specified is 0.5 mg. |
288 | $97 | $461 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
263 | $11 | $100 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
251 | $99 | $500 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
227 | $65 | $228 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
177 | $55 | $300 |
| Magnesium level test A blood test to measure the amount of magnesium in your body. This helps check for magnesium deficiency or excess. |
122 | $7 | $75 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
77 | $21 | $150 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
75 | $49 | $175 |
| Normal saline infusion, 1000 cc Administration of 1000 cc of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater solution. |
75 | $2 | $9 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
74 | $10 | $100 |
| Magnesium sulfate injection, per 500 mg An injection of magnesium sulfate administered in 500 mg increments. |
66 | $1 | $1 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
53 | $91 | $238 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
52 | $1 | $3 |
| Subcutaneous or intramuscular chemotherapy injection This procedure involves administering anti-cancer hormonal medication through an injection into the tissue under the skin or into a muscle. |
47 | $26 | $300 |
| Lactate dehydrogenase (LDH) level test A blood test that measures the amount of lactate dehydrogenase, an enzyme found in many body tissues. It helps assess tissue damage or disease. |
45 | $6 | $100 |
| On-body injector for subcutaneous injection A device is applied to the skin to automatically deliver a medication injection under the skin. |
38 | $14 | $100 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
33 | $49 | $250 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
30 | $22 | $150 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
25 | $123 | $440 |
| Intravenous drug injection A procedure involving the administration of a medication or substance directly into a vein. |
20 | $29 | $200 |
| Irrigation of implanted venous access device This procedure involves flushing an implanted venous access device to clear blockages or maintain patency. It ensures the device remains functional for delivering medications or fluids. |
20 | $19 | $150 |
| New patient office visit, complex (60-74 min) | 14 | $155 | $636 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
11 | $129 | $530 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
1.8% high complexity
84.6% medium
13.6% routine
Industry Payment Transparency
Open Payments through 2024 ↗$17,941
Total received (2018-2024)
Avg $2,563/year across 7 years
Top 18% in NY for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
89
Companies
838
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$14,644 (81.6%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$2,106 (11.7%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$1,191 (6.6%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$4,102
2023
$6,153
2022
$2,698
2021
$1,113
2020
$463
2019
$1,596
2018
$1,815
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
AstraZeneca Pharmaceuticals LP
$1,191
ABBVIE INC.
$283
E.R. Squibb & Sons, L.L.C.
$226
PFIZER INC.
$222
Janssen Biotech, Inc.
$214
PharmaEssentia USA Corporation
$193
Merck Sharp & Dohme LLC
$173
Immunocore Limited
$138
GENZYME CORPORATION
$133
GlaxoSmithKline, LLC.
$115
Genentech USA, Inc.
$109
Daiichi Sankyo Inc.
$92
Incyte Corporation
$79
ARRAY BIOPHARMA INC
$75
JAZZ PHARMACEUTICALS INC.
$68
Novartis Pharmaceuticals Corporation
$62
Sumitomo Pharma America, Inc.
$53
Deciphera Pharmaceuticals Inc.
$46
Celgene Corporation
$45
Ipsen Biopharmaceuticals, Inc
$45
BeiGene USA, Inc.
$41
Eisai Inc.
$40
Acrotech Biopharma Inc.
$38
Alnylam Pharmaceuticals Inc.
$37
Karyopharm Therapeutics Inc.
$36
Takeda Pharmaceuticals U.S.A., Inc.
$36
Lilly USA, LLC
$29
Janssen Pharmaceuticals, Inc
$26
Gilead Sciences, Inc.
$25
Astellas Pharma US Inc
$24
Genmab U.S., Inc.
$23
Myriad Genetic Laboratories, Inc.
$23
SpringWorks Therapeutics, Inc.
$21
Blueprint Medicines Corporation
$18
SERVIER PHARMACEUTICALS LLC
$18
Kyowa Kirin, Inc.
$17
Stemline Therapeutics Inc.
$17
Bayer Healthcare Pharmaceuticals Inc.
$16
ImmunoGen, Inc.
$15
Rigel Pharmaceuticals, Inc.
$15
Aveo Pharmaceuticals, Inc.
$14
ADC Therapeutics America, Inc.
$14
Top 3 companies account for 41.4% of 2024 payments
All-time payments by company (2018-2024) ›
US Oncology Corporate, Inc.
$1,794
AstraZeneca Pharmaceuticals LP
$1,423
Genmab U.S., Inc.
$1,270
Janssen Biotech, Inc.
$1,116
PFIZER INC.
$1,110
Novartis Pharmaceuticals Corporation
$1,004
E.R. Squibb & Sons, L.L.C.
$860
Celgene Corporation
$579
Genentech USA, Inc.
$501
GENZYME CORPORATION
$497
Incyte Corporation
$419
Merck Sharp & Dohme LLC
$346
PharmaEssentia USA Corporation
$309
ABBVIE INC.
$300
Seagen Inc.
$274
GlaxoSmithKline, LLC.
$271
Lilly USA, LLC
$261
Amgen Inc.
$243
ARRAY BIOPHARMA INC
$219
Alexion Pharmaceuticals, Inc.
$218
Pharmacyclics LLC, An AbbVie Company
$210
Epizyme, Inc.,
$200
Novocure GmbH
$200
Merck Sharp & Dohme Corporation
$192
EMD Serono, Inc.
$176
Takeda Pharmaceuticals U.S.A., Inc.
$146
Gilead Sciences, Inc.
$145
Daiichi Sankyo Inc.
$140
Karyopharm Therapeutics Inc.
$139
Immunocore Limited
$138
JAZZ PHARMACEUTICALS INC.
$137
Seattle Genetics, Inc.
$135
Astellas Pharma US Inc
$133
Clovis Oncology, Inc.
$133
Myriad Genetic Laboratories, Inc.
$125
Sumitomo Pharma America, Inc.
$119
Kite Pharma, Inc.
$117
Deciphera Pharmaceuticals Inc.
$110
BeiGene USA, Inc.
$104
SANOFI-AVENTIS U.S. LLC
$86
AVEO Pharmaceuticals, Inc.
$84
Lexicon Pharmaceuticals, Inc.
$79
PUMA BIOTECHNOLOGY, INC.
$78
Acrotech Biopharma Inc.
$78
EISAI INC.
$77
AbbVie, Inc.
$75
Eisai Inc.
$75
ADC Therapeutics America, Inc.
$74
Janssen Pharmaceuticals, Inc
$69
Blueprint Medicines Corporation
$66
Ipsen Biopharmaceuticals, Inc
$66
Apellis Pharmaceuticals, Inc.
$64
Sobi, Inc
$63
Pharmacosmos Therapeutics Inc.
$62
AbbVie Inc.
$55
Kyowa Kirin, Inc.
$54
Sun Pharmaceutical Industries Inc.
$51
Exelixis Inc.
$49
Global Blood Therapeutics, Inc.
$49
MorphoSys, US Inc.
$46
TerSera Therapeutics LLC
$41
EAGLE PHARMACEUTICALS, INC.
$39
Alnylam Pharmaceuticals Inc.
$37
Bayer HealthCare Pharmaceuticals Inc.
$37
Fresenius Kabi USA, LLC
$34
Puma Biotechnology, Inc.
$33
SERVIER PHARMACEUTICALS LLC
$33
G1 Therapeutics, Inc.
$33
Stemline Therapeutics Inc.
$33
ImmunoGen, Inc.
$32
Aveo Pharmaceuticals, Inc.
$28
EUSA Pharma (US) LLC
$28
Regeneron Healthcare Solutions, Inc.
$27
Dova Pharmaceuticals
$27
Pharmacyclics LLC, an AbbVie Company
$24
CTI BioPharma Corp.
$24
TOLMAR Pharmaceuticals, Inc.
$23
Mirati Therapeutics, Inc.
$21
SpringWorks Therapeutics, Inc.
$21
Acrotech Biopharma LLC
$19
Spectrum Pharmaceuticals Inc.
$18
Janssen Scientific Affairs, LLC
$18
Nestle HealthCare Nutrition Inc.
$17
Bayer Healthcare Pharmaceuticals Inc.
$16
Rigel Pharmaceuticals, Inc.
$15
Advanced Accelerator Applications
$14
Boehringer Ingelheim Pharmaceuticals, Inc.
$14
Helsinn Therapeutics (U.S.), Inc.
$13
HOSPIRA, INC.
$8
Top 3 companies account for 25.0% of all-time payments
Associated products mentioned in payments ›
ABECMA · ADAKVEO · ADCETRIS · AFINITOR · ALUNBRIG · AYVAKIT · Abraxane · Alecensa · BAVENCIO · BELEODAQ · BESREMI · BOSULIF · BRAFTOVI · BRUKINSA · Balversa · Bavencio · Blincyto · CABLIVI · CALQUENCE · CARVYKTI · COSELA · CYRAMZA · Cabometyx · Columvi · Creon · DARZALEX · DOPTELET · Doptelet · ELAHERE · ELIGARD · ELIQUIS · ELITEK · ELREXFIO · EMPLICITI · ENHERTU · ENJAYMO · EPKINLY · ERBITUX · ERLEADA · Elahere · Empaveli · Enhertu · Epkinly · Erivedge · Erleada · FOTIVDA · Fabhalta · GAZYVA · GILOTRIF · GIVLAARI · IBRANCE · ICLUSIG · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · INREBIC · Imbruvica · JADENU · JAKAFI · JEMPERLI · JEVTANA · KEYTRUDA · KIMMTRAK · KISQALI · KRAZATI · Kabiven · Kadcyla · Kyprolis · LENVIMA · LIBTAYO · LORBRENA · LUMAKRAS · LUTATHERA · Lenvima · Lunsumio · Lutathera · MEKINIST · MONJUVI · MONOFERRIC · MYLOTARG · MYRISK · NERLYNX · NINLARO · OGSIVEO · OJJAARA · ONUREG · OPDIVO · OPDUALAG · ORGOVYX · OXBRYTA · Onivyde · Orserdu · PADCEV · PEMAZYRE · PEMFEXY · PIQRAY · POTELIGEO · PRECISETUMOR · PROMACTA · Perjeta · Pomalyst · Poteligeo · QINLOCK · REBLOZYL · RETACRIT · ROLVEDON · RYBREVANT · Revlimid · Rezlidhia · Rubraca · SANDOSTATIN · SARCLISA · SCEMBLIX · SOLIRIS · SOMATULINE DEPOT · SUTENT · Stivarga · Sylvant · TABRECTA · TAGRISSO · TASIGNA · TAZVERIK · TECENTRIQ · TECVAYLI · TRUSELTIQ · TUKYSA · Tibsovo · Tivdak · Trodelvy · ULTOMIRIS · Ultomiris · VENCLEXTA · VERZENIO · VONVENDI · VOTRIENT · VYXEOS · Vanflyta · Venclexta · Vonjo · WELIREG · XALKORI · XARELTO · XPOVIO · XTANDI · XYNTHA · Xermelo · Xtandi · YONSA · Yescarta · ZEJULA · ZENPEP · ZEPZELCA · ZYTIGA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (82%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Hematology & oncology specialists within 10 mi
8
Per 100K population
4.0
County median income
$61,059
Nearest hospital
OUR LADY OF LOURDES MEMORIAL HOSPITAL, INC
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Yalamanchili is a mixed practice specialist, with above-average Medicare volume (top 18% in NY), with low-engagement industry engagement in the top 18% of NY peers, with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Yalamanchili experienced with oxaliplatin chemotherapy injection?
Based on Medicare claims data, Dr. Yalamanchili performed 8,898 oxaliplatin chemotherapy injection services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Yalamanchili receive payments from pharmaceutical companies?
Yes. Dr. Yalamanchili received a total of $17,941 from 89 companies across 838 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Yalamanchili's costs compare to other hematology & oncology specialists in Binghamton?
Dr. Yalamanchili's average Medicare payment per service is $11. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Yalamanchili) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Binghamton
Browse hematology & oncology specialists in Binghamton ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in NY
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in NY
Which NY hematology & oncology specialists receive the most from drug and device companies.
By company
US Oncology Corporate, Inc. Payments to Doctors
See all physicians who received payments from US Oncology Corporate, Inc.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
Genmab U.S., Inc. Payments to Doctors
See all physicians who received payments from Genmab U.S., Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology